By Bhanvi Satija and Yadarisa Shabong LONDON (Reuters) -GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit growth, lifting the British company's shares by nearly 7% to their highest level since May 2024. GSK's improved outlook comes as CEO Emma Walmsley prepares to hand over to Luke Miels early next year, with the drugmaker navigating U.S. tariffs and seeking new medicines to offset revenue declines as some top-selling drugs go off pat ...

By Bhanvi Satija and Yadarisa Shabong LONDON (Reuters) -GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer medicines posted double digit growth, lifting the British drugmaker's shares. Although U.S. sales of its shingles vaccine Shingrix fell sharply, its shares gained as much as 4.3% to their highest level since May 2024. The stock, which has risen 25% so far in 2025, was up 2.16% at 1040 GMT. GSK's improved outlook comes as CEO Emma Walmsley prepares to hand ...

By Bhanvi Satija and Yadarisa Shabong LONDON (Reuters) -GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer medicines posted double digit growth, lifting the British drugmaker's shares to their highest level since mid-2024. Although GSK saw a sharp slide in U.S. sales of its shingles vaccine Shingrix, its shares added almost 4% to the gains of around 25% they have notched up so far this year. GSK's improved outlook comes as CEO Emma Walmsley prepares to hand ov ...

By Rishav Chatterjee (Reuters) -Australian biotech CSL on Tuesday delayed its planned vaccine division spin-off and cut earnings forecasts due to a bigger-than-expected decline in U.S. flu vaccination rates, sending its shares down as much as 16.6%. The company told shareholders in August that it would spin off CSL Seqirus into a listed entity on the Australian Securities Exchange by next June as part of a broader restructuring plan that also involved cutting 3,000 jobs. At that time, it believed vaccin ...